Trastuzumab is a humanized monoclonal antibody that binds HER2 specifically and thereby inhibits its homodimerization and phosphorylation, resulting in inhibition of the proliferation of HER2-overexpressing tumor cells [1]. Here, ERBB2 is linked to neoplasm.